Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 8/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137871 | 0.86 | C5AR1 (0.39) | CXCR3C5AR1TRPM8KCNH2MEN1 | |
| SCHEMBL5135154 | 0.82 | MEN1 (0.40) | C5AR1MEN1KMT2A | |
| SCHEMBL5135226 | 0.82 | MEN1 (0.38) | C5AR1MEN1KMT2A | |
| SCHEMBL5137541 | 0.80 | CXCR3 (0.38) | CXCR3C5AR1TRPM8KCNH2MEN1 | |
| SCHEMBL1912763 | 0.80 | C5AR1 (0.58) | C5AR1 | |
| SCHEMBL14415577 | 0.80 | C5AR1 (0.52) | C5AR1 | |
| SCHEMBL5178967 | 0.79 | C5AR1 (0.45) | C5AR1KCNH2GSK3B | |
| SCHEMBL5134563 | 0.78 | C5AR1 (0.60) | C5AR1MEN1KMT2A | |
| SCHEMBL5136708 | 0.78 | C5AR1 (0.45) | CXCR3C5AR1KCNH2 | |
| SCHEMBL5136271 | 0.77 | MEN1 (0.37) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |